Saira Ahmad, Joe A Wrennall, Alexandra S Goriounova, Malika Sekhri, Jason A Iskarpatyoti, Arunava Ghosh, Sabri H Abdelwahab, Alexis Voeller, Mani Rai, Rahul Y Mahida, Krzysztof Krajewski, Diane M Ignar, Alon Greenbaum, Timothy P Moran, Stephen L Tilley, David R Thickett, M Flori Sassano, Robert Tarran
Rationale: Acute Respiratory Distress Syndrome (ARDS) has an unacceptably high mortality rate (35%) and is without effective therapy. Orai1 is a Ca2+ channel involved in store operated Ca2+ entry (SOCE), a process that exquisitely regulates inflammation. Orai1 is considered a druggable target, but to date, no Orai1-specific inhibitors exist. Objectives: To evaluate whether ELD607, a first-in-class Orai1 antagonist, can treat ARDS caused by bacterial pneumonia in preclinical models. Methods: ELD607 pharmacology was evaluated in HEK293T cells and freshly-isolated ARDS patient immune cells...
November 16, 2023: American Journal of Respiratory and Critical Care Medicine